



February 2, 2008

MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

VALENCIA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 6, 2008 at 1:40 PM ET at the Grand Hyatt Hotel in New York, NY.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at <http://www.mannkindcorp.com>. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere[®] Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit <http://www.mannkindcorp.com>.

SOURCE MannKind Corporation -0- 02/01/2008 /CONTACT: Dick Anderson, Chief Financial Officer of MannKind Corporation, +1-661-775-5302, danderson@mannkindcorp.com / Web site: <http://www.mannkindcorp.com> / (MNKD)

CO: MannKind Corporation ST: California, New York IN: HEA MTC BIO SU: TDS CCA

SB-WB -- LAF091 -- 7708 02/01/2008 17:45 EST <http://www.prnewswire.com>